P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature

During the past few decades, researchers have been looking for parameters with an impact on the prognosis of patients with astrocytic tumors. p53 is one of the most widely investigated molecules in human gliomas. We aimed to comprehensively review the evidence for the prognostic usefulness of p53 immunohistochemical expression in paraffin-embedded tissue specimens from diffusely infiltrating astrocytomas. We conducted a systematic review of the PubMed database through December 2007 to identify cohort studies that evaluated p53 immunohistochemical expression as a prognostic marker for human astrocytomas. Estimates of significance were extracted from association tests and hazard ratios with 95% CI from actuarial curves and Cox regression analyses. A meta-analysis was performed on the studies that applied Cox models and had adjusted the hazard ratio of p53 expression with tumor grade and patients’ age. We reviewed 44 publications (including 3,627 patients), 14 of which included the estimates (HR and 95% CI) derived from Cox regression. Descriptive analysis showed that most of the published articles did not contain information on important variables such as sex and age (missing from 25% and 11% of studies, respectively), previous treatment, tissue-retrieval and follow-up period (56%). The quantitative synthesis showed that p53 expression is not a significant prognostic factor (combined HR = 1.034, P = 0.531). There was no significant between-study heterogeneity and publication bias. A second meta-analysis performed only on glioblastomas showed that the overall risk of mortality in these tumors was −0.123 (−0.346 to 0.100) and was not statistically significant. After almost 20 years of research, published evidence does not substantiate the usefulness of p53 immunohistochemical expression as a prognostic marker in patients with astrocytic neoplasms.

[1]  F. Yamasaki,et al.  Prognosis of cerebellar glioblastomas: correlation between prognosis and immunoreactivity for epidermal growth factor receptor compared with supratentorial glioblastomas. , 2006, Anticancer research.

[2]  H. Haapasalo,et al.  Low expression of p27 indicates a poor prognosis in patients with high‐grade astrocytomas , 2003, Cancer.

[3]  P. Deb,et al.  Gemistocytic astrocytomas: histomorphology, proliferative potential and genetic alterations – a study of 32 cases , 2006, Journal of Neuro-Oncology.

[4]  A. Korshunov,et al.  Immunohistochemical Markers for Prognosis of Cerebral Glioblastomas , 2002, Journal of Neuro-Oncology.

[5]  D. Ellison,et al.  p53 status has no prognostic significance in glioblastomas treated with radiotherapy. , 1997, Clinical neuropathology.

[6]  C. Marosi,et al.  Prognostic relevance of p53 protein expression in glioblastoma. , 2002, Oncology reports.

[7]  K. Hess,et al.  Prognostic significance of p53 immunoreactivity in patients with glioma. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  Peter Tugwell,et al.  How to Use an Article about Prognosis , 1995 .

[9]  J. Stávale,et al.  Gemistocytes in astrocytomas: Are they a significant prognostic factor? , 2006, Journal of Neuro-Oncology.

[10]  Ochi,et al.  Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas , 1998, Neuropathology and applied neurobiology.

[11]  S. Tsunoda,et al.  Retinoblastoma protein expression and MIB‐1 correlate with survival of patients with malignant astrocytoma , 1997, Cancer.

[12]  R. Clatterbuck,et al.  The Prognostic Value of Tumor Markers in Patients with Glioblastoma Multiforme: Analysis of 32 Patients and Review of the Literature , 2001, Journal of Neuro-Oncology.

[13]  M. Karagas,et al.  A population-based study of immunohistochemical detection of p53 alteration in bladder cancer , 2004, British Journal of Cancer.

[14]  B. Scheithauer,et al.  Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors , 1999, Cancer.

[15]  P. Okunieff,et al.  Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage , 2004, British Journal of Cancer.

[16]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[17]  P. Korkolopoulou,et al.  MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. , 1997, British Journal of Cancer.

[18]  B. Scheithauer,et al.  Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. , 1997, Journal of neurosurgery.

[19]  S. Al-Sarraj,et al.  p53 immunoreactivity in astrocytomas and its relationship to survival. , 1995, British journal of neurosurgery.

[20]  C. Cordon-Cardo p53 and RB: simple interesting correlates or tumor markers of critical predictive nature? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Barbareschi,et al.  p53 protein in low-grade astrocytomas: a study with long-term follow-up. , 1994, British Journal of Cancer.

[22]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[23]  J. Shinoda,et al.  Prognostic factors in supratentorial WHO grade II astrocytoma in adults. , 1998, British journal of neurosurgery.

[24]  H. Mehdorn,et al.  Age-related Expression of p53, Mdm2, EGFR and Msh2 in Glioblastoma Multiforme , 2003, Zentralblatt fur Neurochirurgie.

[25]  J. Acebes,et al.  Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas , 2003, Cancer.

[26]  K. Aldape,et al.  Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  T. Montine,et al.  Prognostic Significance of p53 Immunoreactivity in Adult Patients with Supratentorial Fibrillary Astrocytic Neoplasms , 1994, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[28]  J. Lafitte,et al.  Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. , 2001, The European respiratory journal.

[29]  A. Rougier,et al.  p53 protein expression in grade II astrocytomas: immunohistochemical study of 100 cases with long-term follow-up. , 1998, Pathology, research and practice.

[30]  R. Bast,et al.  2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Korshunov,et al.  Immunohistochemical Markers for Prognosis of Anaplastic Astrocytomas , 2002, Journal of Neuro-Oncology.

[32]  Gordon H. Guyatt,et al.  Users' Guides to the Medical Literature: V. How to Use an Article About Prognosis , 1994 .

[33]  Y. Soini,et al.  p53 immunohistochemical positivity as a prognostic marker in intracranial tumours , 1994, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[34]  David R. Jones,et al.  A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma. , 2003, Health technology assessment.

[35]  M. Sharma,et al.  Recurrent astrocytic tumours - a study of p53 immunoreactivity and malignant progression , 2002, British journal of neurosurgery.

[36]  Muyang Li,et al.  A dynamic role of HAUSP in the p53-Mdm2 pathway. , 2004, Molecular cell.

[37]  M. Parmar,et al.  Meta-analysis of the literature or of individual patient data: is there a difference? , 1993, The Lancet.

[38]  D. Wynford‐Thomas P53 in tumour pathology: Can we trust immunocytochemistry? , 1992, The Journal of pathology.

[39]  Susan M. Chang,et al.  Glioblastoma Patients Epidermal Growth Factor Receptor , and Survival in Analysis of Complex Relationships between Age , p 53 , Updated , 2001 .

[40]  P Tugwell,et al.  Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. , 1994, JAMA.

[41]  N. Malats,et al.  P53 as a prognostic marker for bladder cancer: a meta-analysis and review. , 2005, The Lancet. Oncology.

[42]  D. Ellison,et al.  Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[43]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[44]  Charles Duyckaerts,et al.  The 2007 WHO classification of tumors of the central nervous system – what has changed? , 2008, Current opinion in neurology.

[45]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[46]  M. Saegusa,et al.  Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics, and survival. , 2001, Journal of clinical pathology.

[47]  Salmi,et al.  Clinicopathological correlation of cell proliferation, apoptosis and p53 in cerebellar pilocytic astrocytomas , 1999, Neuropathology and applied neurobiology.

[48]  P. Kleihues,et al.  Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  A. Kaye,et al.  Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma. , 1995, Neurosurgery.

[50]  N. Rainov,et al.  Prognostic factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survival , 1997, Journal of Neuro-Oncology.

[51]  M. Hilvo,et al.  Expression of Carbonic Anhydrase IX in Astrocytic Tumors Predicts Poor Prognosis , 2006, Clinical Cancer Research.

[52]  C. Cordon-Cardo,et al.  p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns , 1994, International journal of cancer.

[53]  Webster K. Cavenee,et al.  Erratum: The 2007 WHO classification of tumours of the central nervous system (Acta Neuropathol (2007) vol. 114 (97-109)) , 2007 .

[54]  S. Gruber,et al.  HMG CoA reductase inhibitors and the risk of colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  N. Ishii,et al.  Are p53 mutations and p53 overexpression prognostic factors for astrocytic tumors? , 1998, Critical reviews in neurosurgery : CR.

[56]  R. Hellman,et al.  Correlation of tumor p53 and PCNA with response and survival of glioblastoma in patients treated with an ECOG protocol of pre-irradiation chemotherapy. , 1999, Clinical neuropathology.

[57]  S. Tripp,et al.  Epidermal Growth Factor Receptor Gene Amplification and Protein Expression in Glioblastoma Multiforme: Prognostic Significance and Relationship to Other Prognostic Factors , 2006, Applied immunohistochemistry & molecular morphology : AIMM.

[58]  W. Sauerbrei,et al.  Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. , 1994, Journal of the National Cancer Institute.

[59]  H. Thames,et al.  The challenge of p53 as prognostic and predictive factor in gliomas. , 2000, Cancer treatment reviews.

[60]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[61]  T. Yoshimine,et al.  Chromosome 17 allelic loss in astrocytic tumors and its clinico-pathologic implications. , 1997, Clinical neuropathology.

[62]  R. Perry,et al.  Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. , 1992, British Journal of Cancer.

[63]  B. Anandh,et al.  Expression of p53, EGFR, pRb and bcl-2 Proteins in Pediatric Glioblastoma Multiforme: A Study of 54 Patients , 2005, Pediatric Neurosurgery.

[64]  S. Love,et al.  Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy. , 1998, Neurosurgery.

[65]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.

[66]  A. Hilbig,et al.  The role of apoptosis, cell proliferation index, bcl-2, and p53 in glioblastoma prognosis. , 2004, Arquivos de neuro-psiquiatria.

[67]  Sally Freels,et al.  Extracting summary statistics to perform meta‐analysis of the published literature for survival endpoints , 2004 .

[68]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.